Specific immunotherapy in pollen allergy

Current Opinion in Molecular Therapeutics

Volumn 9, Issue 2, 2007, Pages 160-167

  Wallner, Michael ^a   Briza, Peter ^a   Thalhamer, Josef ^a   Ferreira, Fatima ^a  

^a UNIVERSITY OF SALZBURG   (Austria)

Author keywords

Allergen specific immunotherapy; DNA vaccines; Genetically engineered allergen vaccines; Hypoallergens; Peptide immunotherapy; Pollen allergy; Recombinant allergens

Indexed keywords

ALLERGEN; ALUMINUM HYDROXIDE; ANTIFUNGAL AGENT; GRASS POLLEN EXTRACT; IMIDAZOQUINOLINE DERIVATIVE; IMMUNOLOGICAL ADJUVANT; LIPOPOLYSACCHARIDE; MICROBICIDE; POLLEN ALLERGEN PH1 P1; POLLEN ALLERGEN PH1 P2; POLLEN ALLERGEN PH1 P5A; POLLEN ALLERGEN PH1 P5B; POLLEN ALLERGEN PH1 P6; POLLEN ANTIGEN; RAGWEED ANTIGEN; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; NONHUMAN; POLLEN ALLERGY; REVIEW; RHINOCONJUNCTIVITIS;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; ANIMALS; CLINICAL TRIALS; DRUG ADMINISTRATION ROUTES; HUMANS; IMMUNOTHERAPY; RHINITIS, ALLERGIC, SEASONAL;

AMBROSIA;

EID: 34247180803     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Kay AB: Allergy and allergic diseases. Second of two parts. N Engl J Med (2001) 344(2):109-113.
2. Kay AB: Allergy and allergic diseases. First of two parts. N Engl J Med (2001) 344(1):30-37.
3. Bousquet J, Lockey R, Malling HJ: Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol (1998) 102(4 Pt 1):558-562.
4. Larche M, Akdis CA, Valenta R: Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol (2006) 6(10):761-771. •• This paper provides an excellent review of the developments in allergenspecific immunotherapy.
5. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med (1999) 341(7):468-475.
6. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, Koivikko A, Koller DY, Niggemann B, Norberg LA, Urbanek R et al: Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol (2002) 109(2):251-256.
7. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S: Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy (2001) 31(9):1392-1397.
8. Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR: Grass pollen immunotherapy for seasonal rhinitis and asthma: A randomized, controlled trial. J Allergy Clin Immunol (2001) 107(1):87-93.
9. Ferreira F, Briza P, Infuhr D, Schmidt G, Wallner M, Wopfner N, Thalhamer J, Achatz G: Modified recombinant allergens for safer immunotherapy. Inflamm Allergy Drug Targets (2006) 5(1):5-14.
10. Mothes N, Valenta R, Spitzauer S: Allergy testing: The role of recombinant allergens. Clin Chem Lab Med (2006) 44(2):125-132.
11. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O: Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol (2005) 116(3):608-613. •• This paper describes the first clinical trial of wild-type recombinant allergens administered subcutaneously as a mixture of five molecules.
12. Batard T, Didierlaurent A, Chabre H, Mothes N, Bussieres L, Bohle B, Couret MN, Ball T, Lemoine P, Focks Tejkl M, Chenal A et al: Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy. Int Arch Allergy Immunol (2005) 136(3):239-249.
13. Pauli G, Malling H, Rak S, Pastorello E, Purohit A, Larsen T, Ardvisson M, Kavina A, Szaal S, Schroeder J, Vighi G et al: Clinical efficacy of subcutaneous immunotherapy in birch pollen allergic patients: A randomized, double-blind, placebo-controlled study with recombinant Bet v 1 versus nartural Bet v 1 or standard birch extract. Congress of the European Academy of Allergology and Clinical Immunology, Vienna, Austria (2006) 25:Abs 83. •• This abstract reports data from a clinical trial of a recombinant allergen in comparison with whole pollen extract, which suggest that a recombinant major allergen can substitute complex extracts in SIT.
14. Kahlert H, Grage-Griebenow E, Stuwe HT, Cromwell O, Fiebig H: T cell reactivity with allergoids: Influence of the type of APC. J Immunol (2000) 165(4):1807-1815.
15. Gordon S: Pattern recognition receptors: Doubling up for the innate immune response. Cell (2002) 111(7):927-930.
16. Singh N, Bhatia S, Abraham R, Basu SK, George A, Bal V, Rath S: Modulation of T cell cytokine profiles and peptide-MHC complex availability in vivo by delivery to scavenger receptors via antigen maleylation. J Immunol (1998) 160(10):4869-4880.
17. Cirkovic TD, Bukilica MN, Gavrovic MD, Vujcic ZM, Petrovic S, Jankov RM: Physicochemical and immunologic characterization of low-molecular-weight allergoids of Dactylis glomerata pollen proteins. Allergy (1999) 54(2):128-134.
18. Tighe H, Takabayashi K, Schwartz D, Van Nest G, Tuck S, Eiden JJ, Kagey-Sobotka A, Creticos PS, Lichtenstein LM, Spiegelberg HL, Raz E: Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol (2000) 106(1 Pt 1):124-134.
19. Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT: Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol (2004) 113(6):1144-1151. •• This paper describes the shift of Th2 type immune responses to Th1 immune responses following administration of DNA-allergen conjugates to patients with ragweed pollen allergy.
20. Tulic MK, Fiset PO, Christodoulopoulos P, Vaillancourt P, Desrosiers M, Lavigne F, Eiden J, Hamid Q: Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol (2004) 113(2):235-241. • The paper describes the use of DNA-allergen conjugates for the treatment of allergic rhinitis caused by ragweed pollen.
21. Jahn-Schmid B, Fischer GF, Bohle B, Fae I, Gadermaier G, Dedic A, Ferreira F, Ebner C: Antigen presentation of the immunodominant T-cell epitope of the major mugwort pollen allergen, Art v 1, is associated with the expression of HLA-DRB1 *01. J Allergy Clin Immunol (2005) 115(2):399-404. • An association between HLA-DR1 and mugwort pollen allergy is outlined and an immunodominant T-cell epitope as a candidate for a peptide-based immunotherapy is described.
22. Allergen nomenclature. International Union of Immunological Societies and the World Health Organisation (2007). www.allergen.org
23. Linhart B, Hartl A, Jahn-Schmid B, Verdino P, Keller W, Krauth MT, Valent P, Horak F, Wiedermann U, Thalhamer J, Ebner C et al: A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J Allergy Clin Immunol (2005) 115(5):1010-1016.
24. Bolhaar ST, Zuidmeer L, Ma Y, Ferreira F, Bruijnzeel-Koomen CA, Hoffmann-Sommergruber K, van Ree R, Knulst AC: A mutant of the major apple allergen, Mal d 1, demonstrating hypo-allergenicity in the target organ by double-blind placebo-controlled food challenge. Clin Exp Allergy (2005) 35(12):1638-1644. •• The first food challenge with a recombinant allergen in patients with pollen-food syndrome is described.
25. Ferreira F, Ebner C, Kramer B, Casari G, Briza P, Kungl AJ, Grimm R, Jahn-Schmid B, Breiteneder H, Kraft D, Breitenbach M et al: Modulation of IgE reactivity of allergens by site-directed mutagenesis: Potential use of hypoallergenic variants for immunotherapy. FASEB J (1998) 12(2):231-242.
26. Ma Y, Gadermaier G, Bohle B, Bolhaar S, Knulst A, Markovic-Housley Z, Breiteneder H, Briza P, Hoffmann-Sommergruber K, Ferreira F: Mutational analysis of amino acid positions crucial for IgE-binding epitopes of the major apple (Malus domestica) allergen, Mal d 1. Int Arch Allergy Immunol (2006) 139(1):53-62.
27. Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR, Valent P, Ebner C, Kraft D, Valenta R: Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: Candidates for a novel form of specific immunotherapy. J Clin Invest (1997) 99(7):1673-1681.
28. Vrtala S, Akdis CA, Budak F, Akdis M, Blaser K, Kraft D, Valenta R: T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J Immunol (2000) 165(11):6653-6659.
29. Vrtala S, Hirtenlehner K, Susani M, Akdis M, Kussebi F, Akdis CA, Blaser K, Hufnagl P, Binder BR, Politou A, Pastore A et al: Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J (2001) 15(11):2045-2047.
30. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, Reisinger J, Pelzmann M, Hayek B, Kronqvist M, Gafvelin G et al: Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA (2004) 101(Suppl 2):14677-14682. •• The first clinical trial with a genetically engineered hypoallergen administered subcutaneously is reported.
31. Weiss R, Hammerl P, Hartl A, Hochreiter R, Leitner WW, Scheiblhofer S, Thalhamer J: Design of protective and therapeutic DNA vaccines for the treatment of allergic diseases. Curr Drug Targets Inflamm Allergy (2005) 4(5):585-597.
32. Hochreiter R, Stepanoska T, Ferreira F, Valenta R, Vrtala S, Thalhamer J, Hartl A: Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen. Eur J Immunol (2003) 33(6):1667-1676.
33. Ferreira F, Wallner M, Thalhamer J: Customized antigens for desensitizing allergic patients. Adv Immunol (2004) 84:79-129.
34. Bauer R, Scheiblhofer S, Kern K, Gruber C, Stepanoska T, Thalhamer T, Hauser-Kronberger C, Alinger B, Zoegg T, Gabler M, Ferreira F et al: Generation of hypoallergenic DNA vaccines by forced ubiquitination: Preventive and therapeutic effects in a mouse model of allergy. J Allergy Clin Immunol (2006) 118(1):269-276. •• A general approach to generate hypoallergenic DNA vaccines for allergy is outlined.
35. Gabler M, Scheiblhofer S, Kern K, Leitner WW, Stoecklinger A, Hauser-Kronberger C, Alinger B, Lechner B, Prinz M, Vrtala S, Valenta R et al: Immunization with a low-dose replicon DNA vaccine encoding Phl p 5 effectively prevents allergic sensitization. J Allergy Clin Immunol (2006) 118(3):734-741. • Replicon DNA vaccines have the potential to be developed for human use because of their efficacy at extremely low doses.
36. Wilcock LK, Francis JN, Durham SR: Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells. Clin Exp Allergy (2004) 34(9):1373-1378.
37. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F: A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy (2001) 56(6):498-505.
38. Ormstad H, Groeng EC, Duffort O, Lovik M: The effect of endotoxin on the production of IgE, IgG1 and IgG2a antibodies against the cat allergen Fel d 1 in mice. Toxicology (2003) 188(2-3):309-318.
39. Li XM, Srivastava K, Huleatt JW, Bottomly K, Burks AW, Sampson HA: Engineered recombinant peanut protein and heat-killed Listeria monocytogenes coadministration protects against peanut-induced anaphylaxis in a murine model. J Immunol (2003) 170(6):3289- 3295.
40. Bhatia S, Mukhopadhyay S, Jarman E, Hall G, George A, Basu SK, Rath S, Lamb JR, Bal V: Scavenger receptor-specific allergen delivery elicits IFN-γ-dominated immunity and directs established Th2-dominated responses to a nonallergic phenotype. J Allergy Clin Immunol (2002) 109(2):321-328.
41. + Th2 lymphocytes into IFN-γ-producing cells. J Allergy Clin Immunol (2003) 111(2):380-388.
42. Tsuji M, Matsuda H, Miwa H, Miyazaki S: Antimicrobial-induced release of endotoxin from Pseudomonas aeruginosa: Comparison of in vitro and animal models. J Antimicrob Chemother (2003) 51(2):353-359.
43. Kanda N, Enomoto U, Watanabe S: Anti-mycotics suppress interleukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis. J Invest Dermatol (2001) 117(6):1635-1646.
44. Bohle B, Breitwieser A, Zwolfer B, Jahn-Schmid B, Sara M, Sleytr UB, Ebner C: A novel approach to specific allergy treatment: The recombinant fusion protein of a bacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1) combines reduced allergenicity with immunomodulating capacity. J Immunol (2004) 172(11):6642-6648. • An interesting approach for fusing adjuvant to an allergen by recombinant DNA technology is described.
45. Wilson DR, Lima MT, Durham SR: Sublingual immunotherapy for allergic rhinitis: Systematic review and meta-analysis. Allergy (2005) 60(1):4-12. • This is an excellent review on the efficacy of sublingual immunotherapy.
46. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L: Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy (2006) 61(2):151-165. • An excellent review of the immunological mechanisms underlying sublingual immunotherapy.
47. Roberts G, Hurley C, Turcanu V, Lack G: Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol (2006) 117(2):263-268.
48. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, Rivas MF, Ribel M, Durham SR: Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 118(2):434-440.
49. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A: Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy (2005) 60(6):801-807.
50. Gafvelin G, Thunberg S, Kronqvist M, Gronlund H, Gronneberg R, Troye-Blomberg M, Akdis M, Fiebig H, Purohit A, Horak F, Reisinger J et al: Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol (2005) 138(1):59-66.
51. Tulic MK, Fiset PO, Christodoulopoulos P, Vaillancourt P, Desrosiers M, Lavigne F, Eiden J, Hamid Q: Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol (2004) 113(2):235-241.